damae-medical.com Open in urlscan Pro
2001:41d0:301:3::24  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * DISCOVER DEEPLIVE™
 * LC-OCT™ TECHNOLOGY
 * SKIN ANALYSIS
 * OUR COMPANY
 * NEWS
 * JOBS
 * CONTACT
 *  * Clinical application

 *  * Clinical imaging
    * Skin analysis

 * MENU TITLE
   
    * Single Link
   
   MENU TITLE
   
    * Single Link
   
   MENU TITLE
   
    * Single Link
   
   MENU TITLE
   
    * Single Link


SEE BEYOND APPEARANCES

1 IN 3 CANCERS IS A SKIN CANCER

Skin cancer is the most commonly occurring cancer in humans, with an incidence
that has steadily increased worldwide. The prognosis of advanced melanoma is
poor, and carcinomas are associated with high morbidity.        


60% BIOPSIES RESULT IN BENIGN DIAGNOSES

Although dermoscopy is a useful tool for clinical examination, the sensitivity
of dermoscopic monitoring is limited by melanomas that may arise in normal skin
or in clinically benign nevi that were not initially photographed (link).


20% SKIN CANCERS MISSED AT EARLY STAGE

Dermoscopy improves the diagnostic accuracy for melanoma but only for
experienced examiners. Dermoscopy by untrained or less experienced examiners is
no better than clinical inspection without dermoscopy (link).


DISCOVER DEEPLIVE™

DAMAE Medical develops deepLive™ medical device, the new best-in-class imaging
system pairing penetration and cellular resolution in 3D. deepLive™ is adapted
to the imaging of multiple skin conditions, promoting efficient, reassuring and
non-invasive patient management.



pA

00 : 20 / 02 : 59YO



View The 3-MIN presentation viDEo




BASED ON LC-OCT™ INNOVATIVE TECHNOLOGY


deepLive™ integrates LC-OCT (Line-field Confocal Optical Coherence Tomography)
technology which provides a unique 3D imaging modality, allowing the user to 
 switch from a histology-like vertical mode to a confocal-like horizontal mode,
and to record a 3D stack of tissue volumes in situ. 

DOWNLOAD DEEPLIVE™ BROCHURE




NAVIGATIONS IN LC-OCT™ 3D STACKS

LC-OCT™ imaging of the back of a hand

LC-OCT™ imaging of a fingerprint


USER TESTIMONIAL

Prof. Mariano Suppa from the Dermatology Department of the Erasme Hospital, ULB
Brussels, shares his experience with deepLive™.

pA

00 : 20 / 04 : 05YO



LISTEN TO PROF. SUPPA'S EXPERIENCE



LIST OF PUBLICATIONS

Access to the library on Zotero.org





QUANTITATIVE SKIN ANALYSES
ADAPTED TO YOUR STUDIES

SKIN SURFACE 3D SEGMENTATION

DERMO-EPIDERMAL JUNCTION 3D SEGMENTATION

KERATINOCYTES DISTRIBUTION

KERATINOCYTES DENSITY WITH DEPTH

COLLAGEN FIBERS SEGMENTATION



 1. 
 2. 
 3. 
 4. 
 5. 



OUR COMPANY


2014


> Company established by Anaïs BARUT (CEO), David SIRET (CTO), Arnaud DUBOIS
(CSO) who filed the patent protecting LC-OCT's technology 
> Proof of concept of LC-OCT vertical imaging

2015

> First LC-OCT images performed on fresh biopsies of suspected skin cancer
> Validation of the potential of LC-OCT vertical imaging for the 2 main types of
skin cancer: carcinoma and melanoma

2016

> First clinical demonstrator installed at the Saint-Etienne University Hospital
> Winner of the Digital Innovation Competition organized by Bpifrance
> Signature of the exclusive license agreement for LC-OCT technology

2017

> Closing of a €2 million investment round with Kurma Partners, Idinvest
Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures,
and private investors
> Obtaining ISO 13485 certificate
> First proof of concept of LC-OCT 3D


2018

> Winner of the World Competition of Innovation organized by Bpifrance
> Miniaturized LC-OCT 2D in a handheld probe
> Obtaining CE-marking LC-OCT 2D
> Installation of LC-OCT 2D devices in hospitals
> First scientific publication: A. Dubois and al., “LC-OCT for high-resolution
noninvasive imaging of skin tumors”, JBO 23, 106007

2019

> Miniaturized LC-OCT 3D in a handheld probe  > Obtaining CE-marking LC-OCT 3D
> Manufacturing of 10 LC-OCT 3D devices
> Launch of clinical validation of LC-OCT 3D



2020

> Integration of the live dermoscopic camera inside the handheld probe 
> Obtaining the CE mark for deepLive™
> First descriptive clinical publications
> Commercial launch of deepLive™ in Europe



2021

> 30 centers installed in 9 countries in Europe, Japan and the United States
> Publication of the 50th scientific paper on LC-OCT and its applications
> Implementation of a scalable production strategy with industrial partners


FIRST LC-OCT EN COUPE IMAGING SETUP IN 2014

Laboratoire Charles Fabry, Institut d'Optique Graduate School

DAMAE MEDICAL WAS ESTABLISHED IN SEPTEMBER 2014 BY 3 MEMBERS

From left to right: David SIRET (CTO), Anaïs BARUT (CEO), Pr. Arnaud DUBOIS
(CSO)

DAMAE MEDICAL'S OFFICES ARE LOCATED IN PARIS

About twenty collaborators work in the openspace

DAMAE MEDICAL'S OFFICES ARE LOCATED IN PARIS

These offices house an R&D lab and a production space.

Prof. Arnaud Duboispresents LC-OCT technology

3 key numbers in the development of DAMAE Medical


LATEST NEWS

February 2022

DAMAE MEDICAL RAISES €5M IN SERIES A FINANCING


Read More
May 2021

DISCOVER THE LATEST PUBLICATIONS ON
LC-OCT TECHNOLOGY


Read More
September 2019

DAMAE MEDICAL RECEIVES €2.4 MILLION FROM EUROPEAN UNION’S HORIZON 2020 

Read More

CONTACT US


DAMAE MEDICAL
14 RUE STHRAU
75013 PARIS
FRANCE

M: info@damae-medical.com
P: +33 1 44 49 04 10

If you are looking for a position or an internship, send your CV to
job@damae-medical.com
We will get back to you as soon as possible.




 * CONTACT

 * 
 * 
 * 

© 2022 DAMAE Medical Privacy Policy Legal
info@damae-medical.com